Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Entera Bio to a “sell” rating, while analysts remain divided; the stock has an overall “hold” consensus and a $9.00 average price target.
• Entera Bio opened at $2.87, with a market capitalization of approximately $141.5 million. Its latest quarterly loss of $0.14 per share missed estimates of a $0.08 loss, and analysts expect a full-year loss of $0.34 per share.
• Hedge funds and institutional investors increased their positions in the company, which is developing oral peptide therapies led by EB613, an oral parathyroid hormone candidate for osteoporosis.

Entera Bio (NASDAQ:ENTX - Get Free Report) was upgraded by Wall Street Zen to a "sell" rating in a note issued to investors on Saturday.

A number of other equities analysts have also weighed in on ENTX. HC Wainwright reissued a "buy" rating on shares of Entera Bio in a research report on Wednesday, June 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Entera Bio in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $9.00.

Entera Bio Price Performance

ENTX stock opened at $2.87 on Friday. Entera Bio has a 1-year low of $0.91 and a 1-year high of $4.20. The business has a fifty day moving average price of $1.85 and a 200-day moving average price of $1.49. The stock has a market capitalization of $141.46 million, a P/E ratio of -10.63 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). As a group, analysts anticipate that Entera Bio will post -0.34 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

A number of institutional investors and hedge funds have recently modified their holdings of ENTX. Superstring Capital Management LP bought a new stake in shares of Entera Bio in the fourth quarter worth $33,000. Citadel Advisors LLC lifted its holdings in Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock valued at $77,000 after acquiring an additional 28,322 shares during the period. HighTower Advisors LLC lifted its holdings in Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after acquiring an additional 25,000 shares during the period. Jane Street Group LLC boosted its position in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock worth $144,000 after purchasing an additional 43,536 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock worth $210,000 after purchasing an additional 19,601 shares during the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source